UNICHEMLAB
PharmaceuticalsUnichem Laboratories Ltd.
Unichem Laboratories Ltd. is a pharmaceutical company that was founded in 1944 in Mumbai, India. Over the years, the company has expanded its operations and has become a leading player in the generic drug market in India.
As of 2021, the company is performing well, with a strong presence in both the domestic and international markets. In the fiscal year 2020, the company had revenue of around INR 5,000 crore and a net profit of INR 126 crore.
The product mix of the company includes a range of generic drugs, which include anti-infectives, cardiovascular, central nervous system, gastroenterology, and respiratory, among others. These products account for the majority of the company's revenue and profit.
The major growth drivers for the future include the increasing demand for affordable healthcare, growth in emerging markets, and the increasing demand for generic drugs.
In terms of industry analysis, the pharmaceutical industry in India is highly competitive, with many players operating in the market. Some of the direct competitors of Unichem Laboratories Ltd. include Sun Pharmaceuticals, Cipla, and Dr. Reddy's Laboratories.
- Trades at a P/E of 0, with a return on equity (ROE) of 1.17%.
- UNICHEMLAB is trading above 3 of 5 of its key moving averages (10/20/50/100/200-DMA) — a bullish technical setup.
- Year-to-date it is up 21.3%, and up 13.52% over the past year.
- At ₹536.40 it sits about 63% of the way up its 52-week range (₹278.20–₹687.20).
- Market capitalisation stands at ₹3,781 Cr.
Shareholding data syncs daily.
| Year | Revenue | Net Profit | EPS | NPM |
|---|---|---|---|---|
| Mar 2023 | ₹1,072 Cr | ₹-300.00 Cr | ₹-42.57 | -27.99% |
| Mar 2022 | ₹943 Cr | ₹-55.00 Cr | ₹-7.87 | -5.83% |
| Mar 2021 | ₹1,235 Cr | ₹34 Cr | ₹4.87 | 2.75% |
| Mar 2021 | ₹1,235 Cr | ₹34 Cr | ₹4.87 | 2.75% |
| Mar 2020 | ₹1,211 Cr | ₹-60.00 Cr | ₹-8.55 | -4.95% |
| Mar 2020 | ₹1,211 Cr | ₹-60.00 Cr | ₹-8.55 | -4.95% |
| Mar 2019 | ₹1,180 Cr | ₹-23.80 Cr | ₹0.00 | -2.02% |
| Mar 2019 | ₹1,180 Cr | ₹-23.80 Cr | ₹0.00 | -2.02% |
| Mar 2018 | ₹815 Cr | ₹2,545 Cr | ₹361.82 | 312.42% |
| Mar 2017 | ₹698 Cr | ₹109 Cr | ₹11.96 | 15.58% |
| Mar 2016 | ₹1,333 Cr | ₹108 Cr | ₹11.90 | 8.11% |
| Mar 2015 | ₹1,202 Cr | ₹75 Cr | ₹7.90 | 6.27% |
| Company | P/E | Book Value | Sales Growth |
|---|---|---|---|
| SUNPHARMA SUN PHARMACEUTICAL INDUSTRIES LTD. | 39.1 | ₹98.33 | 10.1% |
| MARKSANS MARKSANS PHARMA LTD. | 23.8 | ₹11.85 | 5.8% |
| MOREPENLAB MOREPEN LABORATORIES LTD. | 20.81 | ₹6.43 | 16.6% |
| NEULANDLAB NEULAND LABORATORIES LTD. | 23.48 | ₹542.16 | 9.35% |
| GUFICBIO Gufic BioSciences Ltd. | 24.16 | ₹10.85 | 20.41% |
| DIVISLAB DIVI'S LABORATORIES LTD. | 41.01 | ₹266.77 | 9.47% |
| DRREDDY DR.REDDY'S LABORATORIES LTD. | 19.73 | ₹852.69 | 1.07% |
| RPGLIFE RPG LIFE SCIENCES LTD. | 17.14 | ₹105.02 | 5.73% |
| GLAND Gland Pharma Ltd | 53.6 | ₹242.00 | — |
| ZYDUSLIFE Zydus Lifesciences Ltd | 8.23 | ₹166.00 | 5% |
| SMSPHARMA SMS PHARMACEUTICALS LTD. | 9.58 | ₹42.07 | -8.73% |
| CIPLA CIPLA LTD. | 15.36 | ₹209.71 | 0.7% |
| Date | Client | Type | Qty | Price |
|---|---|---|---|---|
| 18 Mar 2014 | ANITA PRAKASH MODY | SALE | 9,55,000 | ₹213.38 |
| 18 Mar 2014 | PRAKASH AMRUT MODY | PURCHASE | 9,55,000 | ₹213.38 |
Fundamentals, financials & technicals sourced from niftytrader.in, cached and refreshed periodically.